A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. by Talbot, D, von Pawel, J, Cattell, E, Yule, S, Johnston, C, Zandvliet, A, Huitema, A, Norbury, C, Ellis, P, Bosquee, L, Reck, M